Map - I am not sure we should expect PR like that .,
This is double blind study , so usually one need to wait to the end , when they analyze everything , and which patients was on drug and who was on placebo ..

If any particular patient will be doing worse then they will be able to open and see this particular patient ..

This is how normally it is done , but who knows maybe they will give us a hints , generally how many patients are doing good/better .,

But I will not expect to much of news during the study , except enrollment .It will always be good to see good enrollment ..